文献速递心脑血管急症

替格瑞洛单药治疗与替格瑞洛联合阿司匹林对急性冠脉综合征患者主要出血及心血管事件的影响:TICO随机临床试验

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论ACS药物洗脱支架术后3个月DAPT后改为替格瑞洛单药,较12个月替格瑞洛为基础DAPT降低1年净不良临床事件(3.9% vs 5.9%,HR 0.66)。

TICO多中心随机试验纳入3056例接受药物洗脱支架的ACS患者,比较3个月DAPT后替格瑞洛单药(90 mg每日两次)与替格瑞洛为基础12个月DAPT。1年净不良临床事件(主要出血+不良心脑血管事件复合终点)单药组3.9% vs DAPT组5.9%(绝对差-1.98%,95%CI -3.50%至-0.45%;HR 0.66,95%CI 0.48-0.92;P=0.01)。主要出血单药组1.7% vs DAPT组3.0%(HR 0.56,95%CI 0.34-0.91;P=0.02);主要不良心脑血管事件两组无显著差异(2.3% vs 3.4%,HR 0.69,95%CI 0.45-1.06;P=0.09)。作者结论认为ACS药物洗脱支架术后3个月DAPT后替格瑞洛单药较12个月DAPT在1年复合终点上有适度但有统计学意义的降低,解读时需考虑研究人群及低于预期的事件率。

要点

  • ACS药物洗脱支架术后3个月DAPT后替格瑞洛单药(90 mg每日两次)较替格瑞洛为基础12个月DAPT降低1年净不良临床事件:3.9% vs 5.9%,HR 0.66(95%CI 0.48-0.92),P=0.01。
  • 主要出血单药组1.7% vs DAPT组3.0%,HR 0.56(95%CI 0.34-0.91),P=0.02。
  • 主要不良心脑血管事件两组无显著差异:单药组2.3% vs DAPT组3.4%,HR 0.69(95%CI 0.45-1.06),P=0.09。
  • 10项预设次要终点中8项无显著差异。
  • 作者指出解读时需考虑研究人群及低于预期的事件率。

适用人群与场景

  • 接受药物洗脱支架治疗的急性冠脉综合征患者,来自韩国38个中心,2015年8月至2018年10月纳入,平均年龄61岁,女性628例(20%),ST段抬高型心肌梗死占36%。

处置流程与药物剂量

  • 随机分为替格瑞洛单药组:3个月DAPT后替格瑞洛90 mg每日两次单药治疗(n=1527)。
  • 随机分为替格瑞洛为基础12个月DAPT组(n=1529)。

研究设计与关键结果

  • 多中心随机临床试验,纳入3056例ACS药物洗脱支架术后患者,38个中心,随访至2019年10月完成,2978例(97.4%)完成试验。
  • 主要终点为1年净不良临床事件(主要出血+不良心脑血管事件复合终点:死亡、心肌梗死、支架血栓、卒中或靶血管血运重建):替格瑞洛单药组59例(3.9%)vs 12个月DAPT组89例(5.9%),绝对差-1.98%(95%CI -3.50%至-0.45%),HR 0.66(95%CI 0.48-0.92),P=0.01。
  • 主要出血:单药组1.7% vs DAPT组3.0%,HR 0.56(95%CI 0.34-0.91),P=0.02。
  • 主要不良心脑血管事件:单药组2.3% vs DAPT组3.4%,HR 0.69(95%CI 0.45-1.06),P=0.09,无显著差异。
  • 10项预设次要终点中8项无显著差异。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验(RCT)。
  • 作者结论:在ACS药物洗脱支架术后患者中,3个月DAPT后替格瑞洛单药较替格瑞洛为基础12个月DAPT在1年主要出血和心血管事件复合终点上有适度但有统计学意义的降低。
  • 局限:作者指出解读时需考虑研究人群及低于预期的事件率。

对床旁实践的改变

  • 作者认为,对于接受药物洗脱支架的ACS患者,3个月DAPT后转为替格瑞洛单药(90 mg每日两次)较替格瑞洛为基础12个月DAPT可降低1年净不良临床事件和主要出血,但解读时需考虑本研究人群及低于预期的事件率。

指南或共识出处

  • TICO随机临床试验(ClinicalTrials.gov Identifier: NCT02494895),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).

OBJECTIVE: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents.

DESIGN, SETTING, AND PARTICIPANTS: A randomized multicenter trial was conducted in 3056 patients with ACS treated with drug-eluting stents between August 2015 and October 2018 at 38 centers in South Korea. Follow-up was completed in October 2019.

INTERVENTIONS: Patients were randomized to receive ticagrelor monotherapy (90 mg twice daily) after 3-month DAPT (n = 1527) or ticagrelor-based 12-month DAPT (n = 1529).

MAIN OUTCOMES AND MEASURES: The primary outcome was a 1-year net adverse clinical event, defined as a composite of major bleeding and adverse cardiac and cerebrovascular events (death, myocardial infarction, stent thrombosis, stroke, or target-vessel revascularization). Prespecified secondary outcomes included major bleeding and major adverse cardiac and cerebrovascular events.

RESULTS: Among 3056 patients who were randomized (mean age, 61 years; 628 women [20%]; 36% ST-elevation myocardial infarction), 2978 patients (97.4%) completed the trial. The primary outcome occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 3-month DAPT and in 89 patients (5.9%) receiving ticagrelor-based 12-month DAPT (absolute difference, -1.98% [95% CI, -3.50% to -0.45%]; hazard ratio [HR], 0.66 [95% CI, 0.48 to 0.92]; P = .01). Of 10 prespecified secondary outcomes, 8 showed no significant difference. Major bleeding occurred in 1.7% of patients with ticagrelor monotherapy after 3-month DAPT and in 3.0% of patients with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09).

CONCLUSIONS AND RELEVANCE: Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor-based 12-month dual antiplatelet therapy, resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and cardiovascular events at 1 year. The study population and lower than expected event rates should be considered in interpreting the trial.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02494895.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kim BK, Hong SJ, Cho YH, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020. PMID: 32543684. doi:10.1001/jama.2020.7580

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。